Serum Matrix Metalloproteinase-3 in Comparison with Acute Phase Proteins as a Marker of Disease Activity and Radiographic Damage in Early Rheumatoid Arthritis

Table 1

Demographic, clinical, and laboratory data for the group of RA patients (𝑛=128).

Parameters	Mean	SD
Age (years)	46.5	12.79
Female (%)	102 (79.6)
Ethnic origin: Black %	119 (92.97)
DAS ESR	6.28	1.17
Smoking (%)	28 (21.8)
Nodule (%)	30 (23.4)
Erosions (%)	64 (52.03)
mHAQ-D1	1.72	0.76
Disease duration	11.70	7.11
SJC	3.51	4.08
ESR	45.02	27.64
RF (IU/mL)	515.83	522.099
aCCP (U/mL)	679.74	626.54
CRP (µg/mL)	26.95	33.95
SAA (ug/mL)	66.00	128.54
Hb (g/L)	12.8	1.76
MMP-3: control group (ng/mL)	7.5	5.4
MMP-3 (% elevated)	35.8 (56.3)	43.9
Comp: control group (µg/mL)	1.11	0.44
Comp (% elevated)	1.85 (92.0)	0.77

DAS: disease activity score.
HDA: high disease activity.
SJC: swollen joint count.
RF: rheumatoid factor.
aCCP: anticyclic citrullinated peptide antibodies.
CRP: C-reactive protein.
SAA: serum amyloid A.
Hb: haemoglobin.
ESR: erythrocyte sedimentation rate.
MMP: matrix metalloproteinase.
Comp: cartilage oligomeric protein.